Impact of postoperative hydrocortisone replacement dose on health-related quality of life and metabolic parameters in patients with cured Cushing’s syndrome: randomized, open-label, controlled trial
Endocrine · 08.06.2026 · 91 (1)
DOI: 10.1007/s12020-026-04666-9 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Endocrine, online erschienen am 08.06.2026. Verfasst von Anja Barac Nekic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, University Hospital Centre Zagreb, Kispaticeva 12, Zagreb, 10000, Croatia. baracanja0@gmail.com. Hauptthemen laut MEDLINE: Hydrocortisone, Cushing Syndrome, Quality of Life, Hormone Replacement Therapy. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the effect of postoperative hydrocortisone dosing on health-related quality of life (HRQoL), metabolic parameters, and hypothalamic-pituitary-adrenal (HPA) axis recovery in cured Cushing's syndrome (CS). METHODS: This single-centre, randomized, open-label trial included 42 adults with CS and postoperative hypocortisolism randomised to hydrocortisone dose 15 mg/day or 30 mg/day during the first three postoperative months. HRQoL was assessed with e EQ-5D and SF-36 at baseline, at 1 and 3 months, and final follow-up while metabolic parameters were evaluated at baseline and 3 months. Dose effects on metabolic parameters were evaluated using ANCOVA; and HPA axis recovery was assessed using Kaplan-Meier and Cox regression analyses. RESULTS: No significant between-group differences in HRQoL were observed during the three-month period. EQ-5D visual analogue scale scores improved significantly at the final follow-up in both groups, while SF-36 domain scores showed overall improvement over time. At three months, patients receiving 15 mg/day had lower triglycerides, total cholesterol and, HbA1c levels; after adjustment for baseline values, hydrocortisone dose independently affected triglycerides and total cholesterol. No adrenal crises occurred, and there was no excess of acute intercurrent illness or hospitalization in the lower-dose group. HPA axis recovery occurred in 71% of patients and was not associated with hydrocortisone dose. CONCLUSIONS: In cured CS, 15 mg/day hydrocortisone does not worsen HRQoL and had better metabolic profile. HRQoL improves over time irrespective of dose suggesting no benefit from supraphysiological hydrocortisone replacement after curative surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, University Hospital Centre Zagreb, Kispaticeva 12, Zagreb, 10000, Croatia. baracanja0@gmail.com.
- Division of Endocrinology, University Hospital Centre Zagreb, Kispaticeva 12, Zagreb, 10000, Croatia.
- School of Medicine, University of Zagreb, Salata 3, Zagreb, 10000, Croatia.
ORCID-Profile: Anja Barac Nekic, Darko Kastelan, Mirsala Solak, Tanja Skoric Polovina, Annemarie Balasko, Ivana Kraljevic
Zitieren
APA
Nekic, A. B., Kastelan, D., Solak, M., Polovina, T. S., Balasko, A., & Kraljevic, I. (2026). Impact of postoperative hydrocortisone replacement dose on health-related quality of life and metabolic parameters in patients with cured Cushing’s syndrome: randomized, open-label, controlled trial. Endocrine, 91(1). https://doi.org/10.1007/s12020-026-04666-9
Vancouver
Nekic AB, Kastelan D, Solak M, Polovina TS, Balasko A, Kraljevic I. Impact of postoperative hydrocortisone replacement dose on health-related quality of life and metabolic parameters in patients with cured Cushing’s syndrome: randomized, open-label, controlled trial. Endocrine. 2026;91(1). doi:10.1007/s12020-026-04666-9
BibTeX
@article{Nekic2026,
author = {Nekic, Anja Barac and Kastelan, Darko and Solak, Mirsala and Polovina, Tanja Skoric and Balasko, Annemarie and Kraljevic, Ivana},
title = {Impact of postoperative hydrocortisone replacement dose on health-related quality of life and metabolic parameters in patients with cured Cushing’s syndrome: randomized, open-label, controlled trial},
journal = {Endocrine},
year = {2026},
volume = {91},
number = {1},
doi = {10.1007/s12020-026-04666-9}
}
EUVIMED